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Abstract 
First-dose-in-children relies on the prediction of clearance from adults for which little information is 
available on the accuracy of the scaling-approaches applied. For CYP3A-metabolized compounds, 
scaling of clearance is further challenged by different isoforms and by the CYP3A7 to CYP3A4 switch 
at young ages. This investigation aimed to evaluate the accuracy of two frequently used scaling-
approaches and to gain insights into the ontogeny of CYP3A.  Hence, a literature database was 
compiled containing 203 clearance values from term-neonates to adults for 18 CYP3A-metabolized 
compounds. The clearances in adults were scaled to children using i) allometric scaling plus 
maturation function and ii) a mechanistic approach based on the well-stirred model. Three 
maturation functions were separately evaluated. In children >3 months, all approaches were 
interchangeable heeding the maturation function applied and biases were mostly observed in 
children <3 months. The results from a sensitivity analysis indicate that these biases are possibly 
caused by disregarding the CYP3A7 activity which could account for up to 86% of the metabolism in 
term-neonates. Only the mechanistic approach using an overall-CYP3A maturation function led to 
unbiased predictions of clearances across all ages. The current investigation adds to the predictions 





In the light of regulatory requirements to conduct pediatric clinical trials, emphasis has been placed 
on the selection of the first-dose-in-children which often relies on the scaling of clearance from 
adults to children. Two of the scaling approaches previously reported are (i) allometric scaling in 
combination with maturation of clearance for early life1 and (ii)  a mechanistic approach2, 3. The 
allometric scaling predicts total clearance in children by considering a 0.75-exponential relationship 
with body weight. In children younger than approximately 5 years, the gradual development of 
clearance is also attributed to developmental changes, which are described by a single maturation 
function. In contrast, the mechanistic approach is based on the concept of the well-stirred model for 
the prediction of clearance across various ages considering the ontogeny in key physiological 
processes, such as liver blood flow, plasma protein binding, liver size and maturation of the CYP3A 
enzyme activity in the gut and in the liver. This approach has previously been used as basis for 
physiologically-based-pharmacokinetic (PBPK) modules and combined with a population approach 
for prediction of clearance under disease conditions 4, 5.To date, the accuracy of both scaling 
approaches for prediction of the clearance in children has been evaluated to a limited extent for the 
mechanistic approach2, 6, but never for the allometric scaling plus maturation function approach.  
For compounds being metabolized by CYP3A enzymes, scaling of clearance is further hindered by the 
complexity of this metabolic pathway. The CYP3A subfamily is the most abundant group of 
cytochrome P450 isozymes in the liver and consists of at least three isoforms, i.e. CYP3A4, CYP3A5 
and CYP3A77. The different isoforms have different substrate-specificity and ontogeny7,8,9 and are 
often simultaneously involved in the metabolism of pharmaceutical compounds10. In adults, 
compounds that are mainly metabolized by CYP3A4 are likely to be mainly metabolized by CYP3A7 in 
neonates and young infants7, 8, 11. Throughout development, the expression of CYP3A5 has been 
shown to be constant (the fraction of), polymorphically expressed and more limited in its metabolic 
capabilities than CYP3A411-13. The exact and distinct characterization of the developmental 
expression of all these hepatic CYP3A isoforms is confounded by the lack of specific antibodies or 
specific markers for the enzyme activity and; by the often small sample size and the common 
practice of reporting results grouped over large age ranges14, 15. Altogether, it could explain the large 
varying and sometimes contradictory information available on CYP3A-ontogeny in the literature2, 3,
16. To the best of our knowledge, no information is available on how the widely varying public 
information on CYP3A-ontogeny impacts clearance predictions in children. 
The current investigation aims to evaluate the accuracy of allometric scaling plus maturation 
function and the mechanistic approach for the prediction of the clearance in children using a large 
number of clearance values gathered from the literature for different CYP3A-metabolized 
compounds. In addition, three different CYP3A maturation functions previously reported to predict 
pediatric clearances2, 3, 16 were evaluated. Further, a sensitivity analysis was performed to provide 
insights into the ontogeny of the CYP3A isoforms and into the relevance of the minor metabolic 
routes at young ages. Finally, this investigation allowed us challenging our previous findings that the 






From the literature, individual and mean clearance values in adults and children varying from term-
neonates to adolescents were retrieved for a wide range of compounds reported to be primarily 
metabolized by CYP3A enzymes. Compounds known to undergo time-dependent changes in the 
pharmacokinetics and/or compounds of which pharmacokinetics is affected by the disease under 
investigation were excluded from the analysis. Additionally, information on age, body weight, blood-
to-plasma concentration ratio and protein binding were collected. Mean age and body weight were 
used in case of mean clearances. For some compounds, information on the blood-to-plasma 
concentration ratio could not be identified in the literature and therefore the values were assumed 
to be 1. In case of oral administration, bioavailability and potential differences in relative 
bioavailability originating from the use of a pediatric formulation were also collected from the 






ratio xtractionE  
Equation 4.1 
 
where CLadults (mL/min) is the systemic plasma clearance in adults, RB is blood to plasma 
concentration ratio and QHadults (mL/min) is the hepatic blood flow in adults. The hepatic blood flow 
in adults and children was calculated from the sum of hepatic arterial and hepatic portal vein blood 
flow, representing 6.5% and 21% of cardiac output, respectively3. The cardiac output was calculated 
based on an anthropometric equation developed by Simone et al which has been previously 
reviewed by Price et al18. 
Scaling approaches 
For every compound, the median clearance in adults was used to predict the clearance in children 
using two different scaling approaches: i) allometric scaling plus maturation function and ii) 
mechanistic approach, based on the well-stirred model of hepatic clearance. Demographics in adults 
and children were retrieved from the International Commission on the Radiological Protection19. 
Allometric scaling plus maturation function 












where CLadults and CLchildren (mL/min) are the systemic plasma clearances in adults and children, 
respectively. Body weight in adults was assumed to be 70 kg. The f(Age) is the function of age 
representing the ontogeny of the CYP3A enzyme activity (maturation function). 
Mechanistic approach 
The mechanistic approach relies on the calculations of various derived physiological parameters 
prior to the prediction of clearance in children. First, intrinsic clearance in adults was calculated 
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where CLadults and CLchildren (mL/min) are the systemic plasma clearances in adults and children, 
respectively. Body weight in adults was assumed to be 70 kg. The f(Age) is the function of age 
representing the ontogeny of the CYP3A enzyme activity (maturation function). 
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where CLintrinsic, adults (mL/min) is the intrinsic clearance in adults, CLadults (mL/min) is the systemic 
clearance and fuadults is the free fraction in plasma in adults. For orally administered compounds, the 
median of clearance was first corrected using the reported bioavailability. 









where CLintrinsic, MMP  (mL/min/mg) is the intrinsic clearance per mg protein and MPPGL is the 
microsomal protein per gram liver which was equal to 35 mg of microsomal protein per gram liver3. 
LiverWeightadults (g) is the liver weight in adults and was calculated using the anthropometric 
equation developed by Heinemann et al and reviewed by Price et al 18. 




where CLintrinsic,children  (mL/min) is the intrinsic clearance in children, CLinvivo is the in vivo clearance and 
f(Age) is the function of age representing the maturation function that was used to characterize the 
ontogeny of the CYP3A enzyme activity. LiverWeightchildren (g) is the liver weight in children and was 
calculated using the anthropometric equation developed by Ogiu et al and reviewed by Price et al18. 
The concentrations of microsomal protein per gram liver (MPPGL) was assumed to be the same as in 
adults3.  









where CLchildren (mL/min) is the plasma systemic clearance in children, QHchildren (mL/min) is the  
hepatic blood flow in children and fuchildren is the free fraction in plasma. Developmental changes in 
free fraction in plasma were calculated by considering changes in the plasma protein concentration 
as described by Johnson et al3. In compounds with high extraction ratio, Equation 4.3 could not be 
applied as it led to negative values of intrinsic clearance in adults. For these compounds, Equation 
4.6 was not used and the clearance in children was calculated by solely considering developmental 
changes in hepatic blood flow. 
For orally administered compounds, plasma clearance predictions required prediction on the 
bioavailability in children which is influenced by age-related changes in the gut wall metabolism and 
first pass effect as described by Johnson et al3.  
58 
 
Maturation of CYP3A activity 
The allometric scaling and the mechanistic approach were separately investigated using in each 
instance three maturation functions of CYP3A activity in the liver. These maturation functions in 
combination with mechanistic and physiological approaches have been previously reported to 
adequately predict clearance in children2, 3, 16.  
The maturation of CYP3A reported by Edginton et al2 comprises both the developmental changes of 
CYP3A4, CYP3A5 and CYP3A7 isozymes and was derived using in vitro and in vivo data. The 
maturation was reported as fraction of adult values per age and therefore interpolation was 
required to generate a continuous function enabling its use in the current investigation. 
Interpolation was performed using a generalized additive model. On the contrary, the maturation 
used by Johnson et al3 comprises only the developmental changes of CYP3A4/5 and was derived 
using solely in vitro data. This maturation function is characterized by a Hill function as shown in 









where MFCYP3A4/5 is the maturation of CYP3A4/5 activity in the liver as a function of age.  
Another maturation function evaluated in this investigation was the function used by Björkman et al. 
Björkman et al evaluated clearance predictions using a mechanistic approach using solely in vitro 
data from different substrates as reported by Lacroix et al9. In this investigation, only in vitro data 
representing the conversion from testosterone to testosterone 6 -hydroxylation was evaluated, as 
this data represents the activity of CYP3A4 with little activity of CYP3A5 and CYP3A7 in adults. As the 
exact maturation function used by Björkman et al in the predictions was not reported, the original 
data was retrieved from Lacroix et al9 and used to estimate the percentage of adult values in relation 








where MFCYP3A is the maturation function of CYP3A activity in the liver.  
Sensitivity analysis  
A sensitivity analysis was performed to investigate the relevance of multiple CYP enzymes in the 
metabolism of mainly CYP3A-metabolized compounds in children. The maturation of multiple 
isoforms can be described as in Equation 4.9: 
othersACYPACYP MFcMFbMFa)Age(f 7343 Equation 4.9 
where the sum of a, b and c equals 1 and represent the fractions metabolized by each isozyme in 
adults. For the selected compounds, in adults the metabolism occurs mainly via CYP3A4 and thus 
a>>b and a>>c. However, as CYP3A4 activity decreases with decreasing age, the relative contribution 
of other metabolic routes might increase. This was evaluated by plotting the ratio of the maturation 
of different CYP isozymes to the maturation of CYP3A4. The maturation functions of the multiple CYP 
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function of CYP3A7 (MFCYP3A7). The latter maturation function has been derived from the in vitro data 
on dehydroepiandrosterone 16  hydroxylation reported by Lacroix et al9. A non-linear model was 






Further, simulations were performed to separately investigate the relative impact of CYP3A4 and 
CYP3A7 in the metabolism of CYP3A compounds across different ages. The maturation function from 
Johnson et al3 was used as representation of the ontogeny of CYP3A4 activity (Equation 4.7) and the 
maturation function derived on the basis of the in vitro data reported by Lacroix et al9 was used as a 
representation of the ontogeny of CYP3A7 activity (Equation 4.10). The maturation of the overall 
CYP3A activity used was either the one reported by Edginton et al2 or derived using Lacroix et al9 
data. In these simulations, the overall maturation function of CYP3A was assumed to be the sum of 
the activity of CYP3A4 and CYP3A7, thereby disregarding the activity of potential minor metabolic 
routes (Equation 4.11). 
7343 1 ACYPACYP MF)a(MFa)Age(f Equation 4.11 
where a represents the fraction metabolized by CYP3A4 and (1-a), the fraction metabolized by 
CYP3A7 in adults. The value of a was estimated using the maturation function of CYP3A activity 
reported by Edginton et al2 and Lacroix et al9 as reference. 
In all these simulations, the fraction of activity of CYP3A5 was assumed negligible and constant 
across all ages 11, 13.This makes the CYP3A4/5 maturation function previously reported by Johnson et 
al3 representative to CYP3A4. 
Graphical and statistical analysis 
Graphical analyses were performed by assessing the ratio of the predicted clearances to the 
observed clearances versus age. Plots of predicted clearances following allometric scaling plus 
maturation function and using the mechanistic approach were compared for each of the maturation 
functions evaluated. Also, the percentage within two fold range and the average fold error were 
calculated for different age ranges using solely individual observations. The 2-fold range depicts the 
percentage of the observations within two fold of the median prediction and the average fold error 







where afe is average fold error, N is the number of clearance values and CLpredicted and CLobserved is 
respectively the predicted and observed plasma clearance.  
For all observed clearances in children, the median percentage error of the predicted clearance was 












R version 2.12.1 (R Foundation for Statistical Computing, Vienna, Austria) was used for the allometric 
scaling and mechanistic predictions as well as for graphical analysis. In addition, R packages gam 
(generalized additive models) and nls (non-linear least square) were used to fit the reported data on 
CYP3A activity in order to generate continuous maturation functions. 
Results 
Literature database 
The compiled literature database comprised information of 18 compounds as shown in Table 4.1. 
These compounds were mainly low extraction ratio compounds. The calculated extraction ratio is an 
approximation of the “real” extraction ratio since it is strongly influenced specially by 
approximations of the blood-to-plasma concentration ratio which was not always available in the 
literature. The free fraction in plasma varies between compounds and slightly more than a half of 
these compounds were reported to mainly bind to albumin and the rest to alpha-1 acid-glycoprotein 
(AGP). These pharmacokinetic properties are potential factors for differentiation between the 
allometric scaling plus maturation function and the mechanistic approach.  
Table 4.1 Pharmacokinetic properties of the compounds included in the database 
Compound Blood-to-plasma 
concentration ratio 




Alfentanil 0.63 0.16 AGP 0.10 
Amlodipine 1 0.025 Albumin 0.24 
Etoposide 0.519 0.03 Albumin 0.02 
Fentanyl 0.97 0.17 Albumin 0.70 
Imatinib 0.83 0.05 Albumin 0.08 
Indinavir 1.13 0.4 AGP 0.45 
Itraconazole 1 0.01 Albumin 0.28 
Midazolam 0.8 0.03 Albumin 0.31 
Nifedipine 0.59 0.05 Albumin 0.09 
Quinidine 1.84 0.16 AGP 0.27 
Sildenafil 1 0.04 Albumin 0.40 
Sufentanil 1 0.08 AGP 0.66 
Tacrolimus 15.1 0.01 AGP 1.25 
Tamoxifen 1 0.01 Albumin 0.02 
Tamsulosin 0.53 0.02 AGP 0.02 
Teniposide 1 0.01 Albumin 0.02 
Triazolam 0.6 0.1 AGP 0.11 
Zolpidem 0.76 0.08 Albumin 0.15 
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In adults, a total of 44 observed clearance values were collected from which 22 were mean values 
and 22 were individual values (Table S1). The median values for each compound in combination with 
the administration form were used to scale the clearance to children. In children from all ages, a 
total of 159 observed clearance values were available for comparison with calculated clearances 
(Table S2). More than half of these clearance values (64%) were individual reported clearances. In 
adults and children, data following intravenous and oral administration was well balanced. However, 
in children < 3 months most of the  observed data was collected following intravenous 
administration in which systemic clearance predictions were not affected by potential 
misspecification in the scaling of the bioavailability. The data in this age group comprised in total 5 
different compounds with low, intermediate and high extraction ratio including: alfentanil, 
etoposide, fentanyl, midazolam and sildenafil. 
Maturation of CYP3A activity 
Figure 4.1 shows the maturation functions of CYP3A activity applied in the current investigation. In 
children <10 days, the three maturation functions differed by approximately a factor two from each 
other. In children >10 years, the maturation function reported by Johnson et al3 and derived from 
data reported by Lacroix et al9 were similar. These two maturation functions markedly differed from 
the maturation function describing the data reported by Edginton et al2 in children between 6 
months and 5 years. In all cases, above the age of 5 years, the maturation was found to be at adult 
levels.  
 
Figure 4.1 Maturation functions of CYP3A activity applied to the scaling approaches 
The lines represent the maturation functions and the symbols the reported data. 
Scaling approaches 
Figure 4.2 illustrates the ratio of the predicted clearances to the observed clearances for different 
drugs versus age. In children >3 months, the predictive performance was visually similar for all 
scaling approaches applied. In addition, visual inspection showed that predictions in children >3 
months were hardly influenced by the maturation functions used. In children <3 months, the 
predictive performance was strongly biased in all cases, except when using the mechanistic 
approach combined with  the maturation function of CYP3A reported by Edginton et al2 or the 
maturation function of CYP3A derived using data from Lacroix et al9. The maturation of CYP3A4 as 




Figure 4.2 Predictive performance of the clearance scaling approaches when using different maturation functions 
The left plots (a, c and e) represent the ratio of the predicted to the observed clearance when allometric scaling plus 
maturation function was applied. The right plots (b, d and f) represent the ratio of the predicted to the observed 
clearance when the mechanistic approach was applied. The upper plots (a and b) represent the results when using the 
maturation function reported by Johnson et al3, the middle plots (c and d) represent the results when using maturation 
function reported by Edginton et al2 and the lower plots (e and f) represent the results when using maturation function 
derived using in vitro data from Lacroix et al9.  The symbols represent the observed clearance data after intravenous 
(red) and oral (black) administration. Individual data is represented by triangles and average data by x’s. The dotted 
lines illustrate the two fold range. 
These results are confirmed by the values of afe and the percentage 2-fold prediction error 
calculated in Table 4.2 for all ages and for different age groups. The age groups were selected 
following close examination of the results shown in Figure 4.1 and Figure 4.2: 
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children between 6 months and 5 years as the maturation from Edginton et al2 differs from 
the other maturation functions by predicting CYP3A4 activity levels to be above adult levels 
in this age range (Figure 4.1);  
children >3 months and children <3 months as this age is a clear cut off during visual 
inspection of predictive performance (Figure 4.2). 
Table 4.2 Predictive performance of the clearance scaling approaches when using different maturation functions for the 

















Johnson et al3 Edginton et al2 Lacroix et al9 
 0 – 18 years (N=125a/159b)    
afe 0.54 0.75 0.87 1.1 0.67 0.9 
2-fold range 54 68 73 74 60 73 
 >5 years (N=58a/75b)     
afe 0.85 0.82 0.96 0.91 0.88 0.85 
2-fold range 64 71 78 74 67 69 
 6 months – 5 years (N=38a/48b)    
afe 0.72 0.75 1.1 1.1 0.74 0.77 
2-fold range 79 82 84 87 82 84 
 >3 months (N=97a/126b)     
afe 0.81 0.81 1 0.99 0.83 0.83 
2-fold range 69 74 79 78 72 74 
 < 3 months (N=28a/33b)     
afe 0.14 0.57 0.49 1.8 0.32 1.2 
2-fold range 4 46 50 57 18 68 
Only individual observed values were included in these calculations. a number of individual observed values; b total number 
of observed values  
In children >5 years, all predictions were found comparable and unbiased. Slightly better results that 
were obtained when using the maturation function reported by Edginton et al2 are likely to be due 
to the fact that of all three maturation functions investigated, this is the only one that predicts adult 
CYP3A4 activity to be equal to 1. Also in children between 6 months and 5 years, the most precise 
results were obtained using the maturation function reported by Edginton et al2 (afe = 1.1 and 2-fold 
range = 87 %).  In children >6 months, approaches seemed interchangeable when the same 
maturation function was applied. The most pronounced predictive performances were observed in 
children < 3 months. In this age group, scaling results were not interchangeable and allometric 
scaling plus maturation function always showed the worst results when compared to the 
mechanistic approach using the same maturation function. Unbiased results were only observed for 
the mechanistic approach in combination with the maturation function derived from Lacroix et al9 
data (afe = 1.2 and 2-fold range = 68%). This combination of scaling approach and maturation 
function was also shown accurate for the whole age range from 0 to 18 years (afe = 0.9 and 2-fold 
range = 73%) and across the age groups investigated. 
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In this investigation, individual observations had to be compared to average predictions for a certain 
age because literature information did not contain all the demographic information required for 
individual predictions. As a result, the higher percentage errors (>100%) observed is originated from 
individual observations (Table S2).  Also, the great majority of the clearance values outside the 2-fold 
range predictions are represented by individual observations (Figure 4.2). For illustrative purposes, 
Figure 4.3 shows the prediction performance for fentanyl which although unbiased, contained 
observations outside the predicted 2-fold range. Also in Figure 4.3, an example of biased predicted 
performance is displayed using teniposide as an example.  
 
Figure 4.3 Predictive performance of the absolute clearance for fentanyl and teniposide when using the mechanism-
based approach incorporating the maturation function derived using in vitro data from Lacroix et al9. 
The solid line represents the population prediction across different ages and the dotted lines the two fold range. 
Symbols represent the absolute clearances for adults (black) and children (red). Individual data is represented by 
triangles and average data by x’s.  
Sensitivity analysis for understanding the ontogeny of multiple CYP3A isoforms 
Figure 4.4a illustrates the ratio of the maturation of the different CYP isozymes to the maturation of 
CYP3A4/5 activity. Most of the ratios decrease with increasing age and are shown to be the highest 
in neonates. The highest ratio observed is approximately 1300 and concerns the activity of CYP3A7 
in relation to CYP3A4. The ratios of the maturation of the other CYP isozymes to CYP3A4 activity are 
lower than approximately 30. This indicates that even in neonates the activity of the other CYP 
isozymes is likely to be negligible when compared to the activity of CYP3A7.   
Figure 4.4b illustrates the simulations performed to separately investigate the impact of CYP3A4 and 
CYP3A7 in the metabolism of CYP3A compounds across different ages. The activity of minor 
metabolic routes was disregarded in accordance with the results of Figure 4.4a. These simulations 
shows that in adults the relative activity of CYP3A7 is as low as 0.008 (1-a value in Equation 4.11) 
while in neonates this relative activity increases to up to 0.86 due to the increased activity of CYP3A7 
in relation to CYP3A4. In addition, these simulations illustrate that the relative contribution of the 
activity of CYP3A7 is only relevant in children <3 months. The results were shown to be independent 
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Figure 4.4 Sensitivity analysis to investigate the relevance of multiple CYP enzymes in the metabolism of mainly CYP3A 
metabolized compounds and the impact of CYP3A4/5 and CYP3A7 in the metabolism of CYP3A compounds across 
different ages 
The left plot (a) illustrates the ratio of the maturation function of difference CYP enzymes to the maturation function of 
CYP3A4/5 as reported by Johnson et al3. The maturation function for CYP3A7 is derived from in vitro data published by 
Lacroix et al9. The right plot (b) illustrates the ontogeny of the activity of CYP3A7 using data from Lacroix et al9 and 
CYP3A4 as described by Johnson et al3. The symbols are the in vitro data reported by Lacroix et al9. The simulated 
ontogeny activity of overall CYP3A was performed by adding up the activity of CYP3A7 and the activity of CYP3A4 as 
specified in Equation 18. The resulted simulated ontogeny was compared with the references described by Edginton et 
al2 or derived using data from Lacroix et al9.  
Discussion 
There is growing support by regulatory agencies to use scaling approaches for selection of the first-
dose-in-children20. Frequently, the first-dose predictions rely on scaling of the clearance from adults 
for which various approaches can be applied. Two of the scaling approaches previously reported are 
allometric scaling plus maturation function1 and the mechanistic approach2, 3. Very little information 
is known on the accuracy of these scaling approaches2, 6. Further, the prediction of clearance of 
CYP3A-metabolized compounds is confounded by the presence of different with distinct substrate-
specificities and ontogenies that widely vary between references2, 3, 16. Altogether this leads to 
increased uncertainty in the clearance predictions. Hence, in this investigation we aimed to evaluate 
the accuracy and interchangeability of the allometric scaling plus maturation function and; of the 
mechanistic approach for CYP3A-metabolized compounds. For every approach, three CYP3A 
maturation functions previously reported to adequate predict pediatric clearances2, 3, 16 were 
evaluated. Additionally, a sensitivity analysis provided insights into the ontogeny of the CYP3A 
isoforms and into the relevance of the minor metabolic routes at young ages.  
For the retrospective evaluation, a literature database was compiled including 203 clearance values 
from term-neonates to adults of in total 18 compounds (Table S1 and Table S2) for which 79% of the 
total clearance values in children were individual clearances. The results of this retrospective 
evaluation showed that in children >5 years, the allometric scaling plus maturation function and the 
mechanistic approach provided accurate and interchangeable predictions, which most likely can be 
explained by the fact that maturation of enzyme activity in children >5 years is at adult levels. These 
results also show that the age-related developmental changes in key physiological processes 
influencing the clearance seems to be well captured by the allometric scaling function with an 
exponent of 0.75. Our results appear to be in line with conclusions from others that have shown that 
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in children >5 years clearance can be accurately predicted with a simple allometric function6. In 
children <5 years, predictions of clearance using allometric scaling requires it to be combined with a 
maturation function. Despite the widely application of this approach, its accuracy has never been 
determined.  
This investigation illustrates for the first time the accuracy of allometric scaling plus maturation 
function. In children >6 months predictions were interchangeable between scaling approaches and 
within the same maturation function applied. However, in children <3 months, allometric scaling 
plus maturation function resulted in consistently lower clearance predictions (Figure 4.2) and 
accuracy (afe; Table 4.2) when compared to the mechanistic approach. A potential explanation for 
these results is that the maturation function used in combination with allometric scaling is not 
representative for ontogeny of the enzyme activity. This confirms the results of our previous 
investigation17 where simulations have indicated that the maturation function aggregates multiple 
physiological and pharmacokinetic parameters which may include lipophilicity and extraction ratio. 
The mechanistic approach, on the other hand, considers extraction ratio, but disregards lipophilicity 
by assuming blood flow rather than permeation to determine the uptake in the liver. Nonetheless, 
the mechanistic approach combined with the maturation function derived from Lacroix et al9 data 
resulted in unbiased clearance predictions across all ages. This accurate predictive performance was 
obtained without considering substrate-specificity, indicating that it can be neglected at least for the 
compounds evaluated. 
The three CYP3A maturation functions evaluated were selected to be investigated as they have been 
reported to provide adequate predictions of clearance in children2, 3, 16 notwithstanding differences 
in shape of the relationships (Figure 4.1). In children between 6 months and 5 years, the maturation 
function reported by Edginton et al2 showed slightly better predictive performance for clearance 
(Figure 4.2; Table 4.2), showing that CYP3A activity around this age is indeed likely to exceed adult 
levels (Figure 4.1). In children <3 months, under-prediction of the clearance was observed when the 
maturation function reported by Johnson et al3 was used (Figure 4.2; Table 4.2). Also in children <3 
months of age, the maturation function reported by Edginton et al2 and representing overall CYP3A 
activity led to over and under-prediction of clearance. Across all ages, accurate predictions of 
clearance were only observed when the maturation function derived from Lacroix et al9 data was 
used in combination with a mechanistic approach (Table 4.2). In adults, this data essentially 
represents activity of CYP3A4/5 with little activity of CYP3A7, where in young children a CYP3A7 to 
CYP3A4 switch can be expected to influence the clearance. Further, similarities between this derived 
maturation function and the maturation function reported by Edginton et al2 suggests that this data 
indeed represents overall CYP3A activity (Figure 4.1). This opposes initial postulation that it would 
mainly represent CYP3A4 activity9 and supports the need for specific antibodies or specific markers 
for in vitro determination of the enzyme activity14.  
In order to gain more insights on the ontogeny of the CYP3A isoforms and more specifically on the 
switch of CYP3A7 to CYP3A4, a sensitivity analysis was performed. In this analysis the activity of 
CYP3A4 as described by Johnson et al3 and the activity of CYP3A7 derived using data from Lacroix et 
al9 were considered. The activity of overall CYP3A as described by Edginton et al2 or as derived using 
data from Lacroix et al9 were included as references to define the contribution fractions of CYP3A4 
and CYP3A7 activity to the metabolism of different compounds (Equation 4.11). In line with this 
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to 86% of the overall CYP3A activity in neonates (Figure 4.4b). Our results appear to be in line with 
independent in vitro results showing distinct patterns for the developmental expression for CYP3A4 
and CYP3A714. Additionally, the sensitivity analysis shows that the switch of CYP3A7 to CYP3A4 
occurs within the first 3 months of life (Figure 4.4b). Interestingly, when the maturation function 
representing the activity of CYP3A4 as reported by Johnson et al3 was used for the retrospective 
evaluation, biased clearance predictions were observed in children <3 months (Figure 4.2b). In 
addition, the relative activity of non-CYP3A4/5 metabolic routes in relation to the activity of 
CYP3A4/5 was explored. This showed that in children <3 months CYP3A7 activity overwhelmed 
potentially increased activity of minor non-CYP3A4/5 metabolic routes (Figure 4.4a).   
There are two potential limitations in the current investigation. The first is related to the analysis 
results in children < 3 months which were based on a relatively small number of compounds (5 out 
of 18 compounds). However, these compounds displayed varying extraction ratios and this age 
group represented 21% of the total clearance values in children. The second is that the approaches 
evaluated were defined to predict mean clearance values in children, thereby ignoring existence of 
inter-individual variability. From a technical perspective, prediction of individual clearance is 
possible, but was hampered by the lack of (demographic) information at individual levels in both 
adults and children. As a result, predictions of the average clearance in children had to be compared 
with individual clearance values which although sometimes accurate (afe~1) for a certain age range 
still showed a great majority of the clearance values outside the 2-fold range predictions (Table 4.2 
and Table S2). Obviously, in some cases the high 2-fold range predictions can be also the result of 
misspecification in model predictions or study differences in the collected data due to, for example, 
unreported differences in formulations or drug-drug interactions to co-medication. Both situations 
are respectively illustrated in Figure 4.3 which shows the predictive performance of fentanyl and 
teniposide. These results emphasize the need for future research evaluating the accuracy of the 
individual predictions. 
In summary, the retrospective evaluation showed that the allometric scaling plus maturation 
function and the mechanistic approach were shown not to be interchangeable especially in children 
<3 months. Unbiased results across all ages were obtained using the mechanistic approach plus the 
maturation function derived from Lacroix et al9. In addition, the sensitivity analysis provided strong 
evidence that the activity of CYP3A7 should be considered when scaling the clearance to children <3 
months, but also that an overall maturation function for the activity of CYP3A isoforms is sufficient 
to lead to accurate predictions. Further, the need of predicting inter-individual variability on 
clearances was highlighted. Altogether, this investigation adds to reduce uncertainty in the clearance 
predictions, thereby adding to the predictions of the first-dose-in-children of compounds (partially) 
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to 86% of the overall CYP3A activity in neonates (Figure 4.4b). Our results appear to be in line with 
independent in vitro results showing distinct patterns for the developmental expression for CYP3A4 
and CYP3A714. Additionally, the sensitivity analysis shows that the switch of CYP3A7 to CYP3A4 
occurs within the first 3 months of life (Figure 4.4b). Interestingly, when the maturation function 
representing the activity of CYP3A4 as reported by Johnson et al3 was used for the retrospective 
evaluation, biased clearance predictions were observed in children <3 months (Figure 4.2b). In 
addition, the relative activity of non-CYP3A4/5 metabolic routes in relation to the activity of 
CYP3A4/5 was explored. This showed that in children <3 months CYP3A7 activity overwhelmed 
potentially increased activity of minor non-CYP3A4/5 metabolic routes (Figure 4.4a).   
There are two potential limitations in the current investigation. The first is related to the analysis 
results in children < 3 months which were based on a relatively small number of compounds (5 out 
of 18 compounds). However, these compounds displayed varying extraction ratios and this age 
group represented 21% of the total clearance values in children. The second is that the approaches 
evaluated were defined to predict mean clearance values in children, thereby ignoring existence of 
inter-individual variability. From a technical perspective, prediction of individual clearance is 
possible, but was hampered by the lack of (demographic) information at individual levels in both 
adults and children. As a result, predictions of the average clearance in children had to be compared 
with individual clearance values which although sometimes accurate (afe~1) for a certain age range 
still showed a great majority of the clearance values outside the 2-fold range predictions (Table 4.2 
and Table S2). Obviously, in some cases the high 2-fold range predictions can be also the result of 
misspecification in model predictions or study differences in the collected data due to, for example, 
unreported differences in formulations or drug-drug interactions to co-medication. Both situations 
are respectively illustrated in Figure 4.3 which shows the predictive performance of fentanyl and 
teniposide. These results emphasize the need for future research evaluating the accuracy of the 
individual predictions. 
In summary, the retrospective evaluation showed that the allometric scaling plus maturation 
function and the mechanistic approach were shown not to be interchangeable especially in children 
<3 months. Unbiased results across all ages were obtained using the mechanistic approach plus the 
maturation function derived from Lacroix et al9. In addition, the sensitivity analysis provided strong 
evidence that the activity of CYP3A7 should be considered when scaling the clearance to children <3 
months, but also that an overall maturation function for the activity of CYP3A isoforms is sufficient 
to lead to accurate predictions. Further, the need of predicting inter-individual variability on 
clearances was highlighted. Altogether, this investigation adds to reduce uncertainty in the clearance 
predictions, thereby adding to the predictions of the first-dose-in-children of compounds (partially) 
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Table S1 Observed data in adults used for scaling to children  













 Alfentanil      
1 Intravenous Yes 28 66 1 7.2 
1 Intravenous Yes 35 55 1 3.9 
1 Intravenous Yes 32 58 1 2.7 
1 Intravenous Yes 34 60 1 3.9 
1 Intravenous Yes 27 60 1 3.3 
 Amlodipine      
2 Oral No 30 70 0.77 5.9 
 Etoposide      
3 Intravenous No 30 70 1 0.643 
 Fentanyl      
2 Intravenous No 30 70 1 13 
4 Intravenous No 21.5 64 1 23.9 
5 Intravenous No 26.5 61.5 1 15.6 
6 Intravenous No 61 69 1 14.5 
 Imatinib      
7 Oral No 55 69 0.98 1.98 
 Indinavir      
8 Oral Yes 30 70 0.65 11.9 
 Itraconazole      
9 Intravenous No 30 70 1 5.4 
 Midazolam      
10 Intravenous No 22 69 1 7.58 
10 Oral No 22 69 0.24 40 
 Nifedipine      
11 Oral No 22 73 0.43 6.37 
12 Oral No 32.5 75 0.43 6.41 
 Quinidine      
13 Oral Yes 22 61.7 0.8 3.67 
14 Oral No 30 70 0.8 3.9 
 Sildenafil      
15 Oral No 57.7 86.6 0.41 11.3 
16 Oral No 30 70 0.41 23.7 
16 Intravenous No 30 70 1 9.71 
 Sufentanil      
17 Intravenous Yes 26 50 1 7.68 
17 Intravenous Yes 58 61 1 12.2 
17 Intravenous Yes 39 100 1 10 
17 Intravenous Yes 50 63 1 13.4 
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1 Intravenous Yes 34 60 1 3.9 
1 Intravenous Yes 27 60 1 3.3 
 Amlodipine      
2 Oral No 30 70 0.77 5.9 
 Etoposide      
3 Intravenous No 30 70 1 0.643 
 Fentanyl      
2 Intravenous No 30 70 1 13 
4 Intravenous No 21.5 64 1 23.9 
5 Intravenous No 26.5 61.5 1 15.6 
6 Intravenous No 61 69 1 14.5 
 Imatinib      
7 Oral No 55 69 0.98 1.98 
 Indinavir      
8 Oral Yes 30 70 0.65 11.9 
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9 Intravenous No 30 70 1 5.4 
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10 Intravenous No 22 69 1 7.58 
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 Quinidine      
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16 Intravenous No 30 70 1 9.71 
 Sufentanil      
17 Intravenous Yes 26 50 1 7.68 
17 Intravenous Yes 58 61 1 12.2 
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17 Intravenous Yes 22 54 1 15.6 
17 Intravenous Yes 64 57 1 14.8 
17 Intravenous Yes 45 111 1 11.8 
17 Intravenous Yes 64 77 1 12.3 
17 Intravenous Yes 39 72 1 13.5 
 Tacrolimus      
18 Intravenous No 30 70 1 1.6 
 Tamoxifen      
19 Oral No 61 71 0.237 1.65 
 Tamsulosin      
20 Oral No 30 70 1 0.686 
 Teniposide      
21 Intravenous Yes 19 70 1 0.5 
21 Intravenous Yes 19 70 1 0.4 
21 Intravenous Yes 20 70 1 0.1 
21 Intravenous Yes 26 70 1 0.2 
21 Intravenous Yes 26 70 1 0.4 
 Triazolam      
22 Oral No 22.8 83.1 0.53 5.02 
22 Oral No 27 71.5 0.53 6.9 
 Zolpidem      
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